Drug Profile

Budesonide/mesalazine suppository - Dr. Falk Pharma

Alternative Names: mesalazine/budesonide suppository

Latest Information Update: 24 Feb 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dr Falk Pharma
Class Aminosalicylic acids; Anti-inflammatories; Antiallergics; Glucocorticoids; Irritable bowel syndrome therapies; Pregnenediones; Small molecules
Mechanism of Action Glucocorticoid receptor agonists; Lipoxygenase-cyclooxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

24 Feb 2016 No recent reports on development identified - Phase-II for Ulcerative proctitis in Germany (Rectal)
01 Aug 2015 Dr. Falk Pharma completes a phase II trial in Ulcerative proctitis in Germany (Rectal) (NCT01966783)
01 Sep 2013 Phase-II clinical trials in Ulcerative proctitis in Germany (Rectal)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com